CN105349524B - The hybridoma cell strain of anticoagulin VII polyclonal antibody - Google Patents
The hybridoma cell strain of anticoagulin VII polyclonal antibody Download PDFInfo
- Publication number
- CN105349524B CN105349524B CN201510792378.4A CN201510792378A CN105349524B CN 105349524 B CN105349524 B CN 105349524B CN 201510792378 A CN201510792378 A CN 201510792378A CN 105349524 B CN105349524 B CN 105349524B
- Authority
- CN
- China
- Prior art keywords
- cell
- coagulation factor
- factor vii
- mouse
- hybridoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to the hybridoma cell strains and preparation method thereof of secretion anti-human coagulation factor VII polyclonal antibody.Balb/c mouse is immunized as antigen by the conjugate after using bovine serum albumin(BSA) BSA and human blood coagulation factor VII to be coupled in the present invention, its spleen cell and SP2/0 myeloma cell is taken to carry out cell fusion, selective culture is carried out with HAT culture medium, the fused cell for selecting Mouse spleen cells Yu mouse hybridoma cell SP2/0 identifies the hybridoma cell strain of secretion anti-human coagulation factor VII polyclonal antibody finally by ELISA method.Strain of hybridoma strain prepared in accordance with the present invention is preserved in China typical culture collection center, and deposit number is CCTCC C2015195.
Description
Technical field
The present invention relates to hybridoma cell strains and preparation method thereof, and in particular, to anti-human coagulation factor VII Anti-TNF-α
Hybridoma cell strain of body and preparation method thereof.
Background technique
Human blood coagulation factor VII is a kind of single chain glycoprotein of vitamin K dependent synthesized by liver cell, is that body external source is solidifying
The initiation factor of blood approach.Concentration of the human blood coagulation factor VII in blood plasma is only (0.5~2) mg/L, and half-life period is 6~8 small
When, either primary or secondary proconvertin lack in human body, are likely to cause bleeding, or even jeopardize life
Life.Research is it has proven convenient that human blood coagulation factor VII not only plays an important role in terms of physiological hemostasis, but also its blood plasma level
Also there is correlation with some diseases in height gene pleiomorphism.Human blood coagulation factor VII polyclonal antibody is removed for basis
Research is outer, it may also be used for prepares high sterling human blood coagulation factor VII and prepares human blood coagulation factor VII detection reagent.In addition, people's blood coagulation
Factor Ⅴ II coagulation activity and antigenic content detection may be by human blood coagulation factor VII antibody.The country, which has not yet to see, develops people
The report of plasma coagulation factors VII polyclonal antibody, also without high-purity human blood coagulation factor VII product, human blood coagulation used
VII detection reagent is purchased from foreign countries substantially, and to pass through preparation high sterling human blood coagulation factor VII and human blood coagulation factor VII detection examination
Agent must first prepare the how grand antibody of human blood coagulation factor VII.
Thus, there is the demands to human blood coagulation factor VII polyclonal antibody in this field.
Summary of the invention
To solve the above-mentioned problems, the present invention provides a kind of hybridization for secreting anti-human coagulation factor VII polyclonal antibody
Tumor cell strain and preparation method thereof.
In the first aspect, the present invention provides a kind of hybridization for preparing secretion anti-human coagulation factor VII polyclonal antibody
The method (being also referred to as " method of the invention " sometimes herein) of tumor cell strain, the described method comprises the following steps:
1) immunizing antigen is prepared: by homotype bifunctional protein crosslinking agent by human blood coagulation factor VII and bovine serum albumin(BSA)
Coupling, obtains human blood coagulation factor VII-bovine serum albumin(BSA) conjugate；
2) mouse is immunized: using low dose of multiple immunization protocol, utilizing human blood coagulation factor VII-ox obtained in step 1)
Seralbumin conjugate acting immune antigen, is immunized Balb/c mouse；
3) cell fusion: the spleen for the immune Balb/c mouse that SP2/0 murine myeloma cell and step 2) are obtained is thin
Born of the same parents' fusion carries out selective culture in the RPMI-1640 culture medium containing HAT；
4) the selectivity culture of hybridoma: fused cell is selectively trained in HAT culture medium in step 3)
After supporting, the fused cell of Mouse spleen cells and mouse hybridoma cell SP2/0 is selected；And
5) identify: detecting step 4) in the culture supernatant of the hybridoma of fusion that obtains, identification secretes anti-human blood coagulation
The hybridoma cell strain of factor Ⅴ II polyclonal antibody.
In the second aspect, the present invention provides the hybridoma cell strains of secretion anti-human coagulation factor VII polyclonal antibody
(hereinafter sometimes called " hybridoma cell strain of the invention "), the hybridoma cell strain is to prepare by means of the present invention
's.
In a preferred embodiment, strain of hybridoma strain prepared by the method for the present invention was in 2015
November 6 was preserved in China typical culture collection center, address are as follows: in the preservation of Wuhan City, Hubei Province Wuchang District Wuhan University
The heart, deposit number are CCTCC C2015195, culture title are as follows: hybridoma cell strain F7-P-01.
Specific embodiment
Definition:
" protein-crosslinking agent " is small molecule compound, and molecule both ends respectively have one or more for special base
Group (- NH2,-COOH ,-HS etc.) reactive terminal, can be coupled respectively with the active group in biomolecule, to make this
A little molecules are combined together.Protein-crosslinking agent can be divided into homotype bi-functional cross-linking agent (also referred to as " homologous crosslinking agent "), special-shaped pair
Functional cross-link agent (also referred to as " heterologous crosslinking agent ") and photoactivated cross-linking agent (also referred to as " photoreactivity crosslinking agent ") three classes.
The molecule both ends reactive terminal having the same or priming reaction group of homotype bifunctional protein crosslinking agent.It is common
Homotype bi-functional cross-linking agent be well known in the present art, non-limiting example includes but is not limited to that NHS esters crosslinking agent is all
Such as bis- thiobis (sulfonic acid of n-hydroxysuccinimide (NHS), two thiobis (succinyl phosphorons amino propyl acid ester) (DSP) and 3,3'-
Succinimidyl Propionate) (DTSSP), succinic acid suberic acid diimine (DSS) and butadiene-styrene copolymer (BS),
Two succinimide ester of tartaric acid (DST) and Sulfo-DST, bis- (2- [succinimidyloxycarbonyl oxygen) ethyls) sulfone
(BSOCOES) and sulfo-BSOCOES, ethylene glycol bis- [succinimido succinic acid] (EGS) and sulfo-EGS, succinic acid
Suberic acid glutarate (DSG), N, bis- succinimidyl carbonate of N'- (DSC)；Carbodiimide class such as 1- ethyl -3- [3-
Dimethylaminopropyl] carbodiimide hydrochloride (EDC)；Imido esters crosslinking agent such as dimethyl diiminoester (DMA), diformazan
Base imines ester (DMP), two acid imide ester (DMS) of dimethyl benzene, di-tert-butyl peroxide (DTBP)；Sulfydryl reacts class crosslinking agent
Such as 1,4- bis- (3`- [2`- disulfide group pyridine] propionic acid acylamino-) butane (DPDPB)；The 1,5- bis- fluoro- 2 of difluoro bezene derivative,
4- dinitrobenzene (DFDNB), bis- (the fluoro- 3- nitrobenzophenone of 4-) sulfoxides (DFDNPS) etc.；Photoreactivity crosslinking agent class crosslinking agent is all
Such as double-[β-(azido salicyl amino) ethyl] disulphide (BASED)；Aldehyde crosslinking agent such as formaldehyde, glutaraldehyde
Deng；1,4- butanediol glycidaldehyde of di-epoxide class etc.；Hydrazides crosslinking agent such as adipic dihydrazide, carbohydrazide
Deng；Double derivative species crosslinking agent is by the o- tolidine of diazonium, bis-diazotized benzidine etc.；And double alkyl halides
Deng.
Photoreactivity crosslinking agent is the crosslinking agent with photoreactive group.The priming reaction base of homotype bi-functional cross-linking agent
Group is also possible to photoreactive group.
Type, the reactive group, protein binding group, light work of part homotype bifunctional protein crosslinking agent are listed in table 1
The properties such as the property changed.
Table 1
" antibody " (antibody) refers to that the immune system of body under antigenic stimulus, is increased by bone-marrow-derived lymphocyte or memory cell
Grow the immunoglobulin that the thick liquid cell being divided into is generated, can specifically bind with corresponding antigens.
The present invention provides a kind of hybridoma cell strain for secreting anti-human coagulation factor VII polyclonal antibody and its preparation sides
Method.
In one embodiment, the method for the present invention includes the following steps:
1) immunizing antigen is prepared: by homotype bifunctional protein crosslinking agent by human blood coagulation factor VII and bovine serum albumin(BSA)
Coupling, obtains human blood coagulation factor VII-bovine serum albumin(BSA) conjugate；
2) mouse is immunized: using low dose of multiple immunization protocol, utilizing human blood coagulation factor VII-ox obtained in step 1)
Seralbumin conjugate acting immune antigen, is immunized Balb/c mouse；
3) cell fusion: the spleen for the immune Balb/c mouse that SP2/0 murine myeloma cell and step 2) are obtained is thin
Born of the same parents' fusion carries out selective culture in the RPMI-1640 culture medium containing HAT；
4) the selectivity culture of hybridoma: fused cell is selectively trained in HAT culture medium in step 3)
After supporting, the fused cell of Mouse spleen cells and mouse hybridoma cell SP2/0 is selected；And
5) identify: detecting step 4) in the culture supernatant of the hybridoma of fusion that obtains, identification secretes anti-human blood coagulation
The hybridoma cell strain of factor Ⅴ II polyclonal antibody.
In the method for the invention, any homotype bifunctional protein crosslinking agent as known in the art can be used, preferably
Carbodiimide albuminoid crosslinking agent, more preferable EDC.
In the present invention, animal immune is using low dose of multiple immunization protocol, conventional with 100~200 μ by taking mouse as an example
The dose immunization of g/ only, is immunized 3~4 times.One specific immunization protocol example is: the female using immunizing antigen to 7 week old
Balb/c mouse is immunized, and by the immunizing dose of 100 μ g/ only, 1:1 is mixed by volume with Freund's complete adjuvant, and emulsification reaches
To Water-In-Oil shape, by the comlete antigen of emulsification, immune mouse is subcutaneously injected in the nape of the neck multiple spot, after 2 weeks, with same antigen and waits bodies
Long-pending incomplete Freund's adjuvant emulsification, 100 μ g/ only carry out booster immunization, and row third time is immune after 2 weeks, and dosage and method are the same as the
Secondary immunity carries out last time to mouse before cell fusion and impacts immune, the immunizing dose intraperitoneal injection of 100 μ g/ only.
In the method for the invention, the method for cell fusion is unrestricted, can using method as known in the art and
Process.
In the method for the invention, the method for antibody test is unrestricted, can use detection side as known in the art
Method, for example, ELISA method can be used.
By means of the invention it is also possible to filter out the hybridoma of secretion anti-human coagulation factor VII polyclonal antibody
Strain.
As example, the hybridoma of secretion anti-human coagulation factor VII polyclonal antibody of the invention is provided below
One exemplary fabrication flow of strain:
1) preparation of immunizing antigen:
It takes 1mg human blood coagulation factor VII to be dissolved in 0.25mLDMSO solution, EDC is added, is protected from light is aggressively shaken 2 at room temperature
Hour, 4 DEG C reaction overnight, above-mentioned solution is slowly added dropwise in BSA solution, be protected from light at room temperature concussion 2 hours, reaction product in
0.05molL-1It is protected from light dialysis 72 hours in PBS buffer solution, obtains the conjugate of human blood coagulation factor VII Yu carrier protein BSA.
2) mouse immune:
Use human blood coagulation factor VII-BSA conjugate as immunizing antigen, the female Balb/c mouse of 7 week old is exempted from
Epidemic disease, by the immunizing dose of 100 μ g/ only, 1:1 is mixed by volume with Freund's complete adjuvant, and emulsification reaches Water-In-Oil shape, will be emulsified
Comlete antigen, immune Balb/c mouse is subcutaneously injected in the nape of the neck multiple spot, after 2 weeks, not with same antigen and isometric Freund
Freund's complete adjuvant emulsification, 100 μ g/ only carry out booster immunization, and row third time is immune after 2 weeks, and method is immune with second, melt in cell
Last time is carried out to mouse before closing and impacts immune, the immunizing dose intraperitoneal injection of 100 μ g/ only.
3) the selectivity culture of cell fusion and hybridoma:
SP2/0 murine myeloma cell is taken to mix with immune Balb/c Mouse spleen cells in the ratio of 1:5-1:10
Even, 1300rpm is centrifuged 7 minutes, sets the preheating of 40 DEG C of metal baths, is added in 45s with 1mL suction pipe and is preheated to 40 DEG C of 1mL50%
PEG4000, side edged gently vibrate, and 1640 incomplete culture mediums that 30mL is preheated to 37 DEG C are then added in 90s, and room temperature is quiet
It setting 10 minutes, 1000rpm is centrifuged 5 minutes, abandons supernatant, and 1640 culture mediums of the 20mL containing 20% fetal calf serum and HAT are added and are resuspended,
It is dispensed on the culture plate of existing feeder cells, in 5% carbon dioxide incubator culture, after 7 days, observes the growth shape of cell
Condition is swapped out 1/2 culture medium with 1640 culture mediums containing 20% fetal calf serum and HT, after 14 days, use instead 20% fetal calf serum and
HT1640 culture medium culture.
4) hybridoma of identification secretion anti-human coagulation factor VII antibody:
It is 2 μ g/ml that antibody, which is diluted to protein content, with the carbonate of 0.05M pH9.6 coating buffer.Each
Add 50 μ l in the reacting hole of polystyrene board, 4 DEG C overnight.Next day discards solution in hole, washes 3 times with washing buffer, and every time 3
Minute (referred to as washs, similarly hereinafter).Add skimmed milk power (BD company) PBS containing 5% in the reacting hole of each polystyrene board
300 μ l set 37 DEG C and are incubated for 2 hours, are washed out.Add certain diluted 50 μ l of measuring samples in the above-mentioned reacting hole being coated with
In, it sets 37 DEG C and is incubated for 1 hour, be washed out (while doing blank well, negative control hole and Positive control wells).In each reacting hole
In, the 50 μ l of enzyme labelled antibody (by specification is diluted) of diluted is added, 37 DEG C are incubated for 1 hour, are washed out.In
The 50 μ l of tmb substrate solution of Extemporaneous is added in each reacting hole, develops the color 15 minutes at 37 DEG C.2M sulphur is added in each reacting hole
50 μ l of acid terminate reaction.In the result that in white background, directly detects by an unaided eye: color is deeper in reacting hole, and positive degree is stronger,
To be colourless or extremely shallow, the depth of the be in color of foundation is indicated negative reaction with "+", "-" number.As a kind of alternative judgement side
Formula can also survey each hole OD on ELISA detector in 450nm and 630 double UV check OD values after returning to zero with blank control wells
Value, it is as positive if more than 2.1 times of defined negative control OD value.
In a preferred embodiment, hybridoma cell strain prepared by the method for the present invention is named as F7-P-
01, and China typical culture collection center, address are deposited on November 6th, 2015 are as follows: Wuhan City, Hubei Province Wuchang District is military
Chinese university collection, deposit number are CCTCC C2015195.
The preparation method of hybridoma cell strains F7-P-01 the following steps are included:
Human blood coagulation factor VII (DMSO) solution is prepared, 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide is added
(EDC) it is activated.Above-mentioned solution is slowly added dropwise and carries out human blood coagulation factor VII and BSA in bovine serum albumin(BSA) (BSA) solution
Coupling, reaction product with phosphate buffer (PBS) dialyse, obtain the coupling of human blood coagulation factor VII Yu carrier protein BSA
Object.Serum titer is taken to be greater than 1:10000 by immune mouse tail vein blood with enzyme-linked immunosorbent assay detection after four times immune
The splenocyte of mouse merged with myeloma cell SP2/0；With containing hypoxanthine (H), aminopterin-induced syndrome (A) and thymidine
(T) RPMI-1640 of selective culture solution (HAT is purchased from SIGMA company) and 20% fetal calf serum (is purchased from HYCLONE public affairs
Department) culture solution culture, seven days cells initially form colony after fusion；It is coated with human coagulation factor VII antigen, by enzyme-linked
Immunoadsorption assay (ELISA) identification, obtains the hybridoma cell strain of stably excreting anti-human coagulation factor VII polyclonal antibody,
It is named as F7-P-01.Using this strain of hybridoma with 1 × 106A/amount intraperitoneal injection only is in advance with atoleine sensitization
The Balb/c female mice of 8-10 week old, acquires ascites after 10-14 days, detecting ascites by enzyme-linked immunosorbent assay is sun
Property, and prove that it can identify human blood coagulation factor VII by immunoblotting.It is surveyed through mouse polyclonal antibody subclass parting kit
The polyclonal antibody hypotype for determining hybridoma cell strain F7-P-01 secretion is IgM.
Embodiment
1, material and instrument
1.1 cell strains, tissue specimen and animal
A. it myeloma cell (SP2/0): derives from ATCC (American Type Culture collection warehousing).
B.Balb/c mouse: it is purchased from Tsinghua University animal platform.
1.2 main agents
A. Freund's complete adjuvant, freund 's incomplete adjuvant, HAT, HT, TMB, PEG (molecular weight 4000), EDC: are purchased from
Sigma company；
B.HRP marks sheep anti-mouse igg: being purchased from Gibco company；
C.RPMI1640 culture medium: it is purchased from HyClone company；
D. cellulose acetate film (NC): it is purchased from Hybond company；
E. fetal calf serum: it is purchased from PAN company；
F. mouse polyclonal antibody subclass parting kit: purchased from Thermo points of departments；
G. it is coated with buffer: the sodium carbonate of 0.795g and the sodium bicarbonate group of 1.465g being added in every 500mL deionized water
At pH value 9.6.
H. the disodium hydrogen phosphate of 9.2g and the lemon of 2.55g substrate buffer solution: are added in every 500mL deionized water
Acid composition, pH value 5.0.
I.TMB (tetramethyl benzidine) uses liquid: TMB (10mg/5mL dehydrated alcohol) 0.5mL substrate buffer solution (pH5.5)
10mL 30%H2O20.01μl；
J. 7.5% sodium bicarbonate 15mL group incomplete 1640 culture medium: is added in the 1640 culture medium stoste of every 500mL
At.
K. the fetal calf serum composition of 20mL complete 1640 culture medium: is added in every incomplete 1640 culture medium of 80mL.
L. antibody diluent: the BSA composition of 0.1g is added in the PBS of every 100mL.
M. washing buffer: the Tween-20 composition of 0.5mL is added in the PBS of every 100mL.
N.PEG prepares liquid: 7.5% carbonic acid of the DMSO and 0.1mL of 1mL being added in every incomplete 1640 culture medium of 8.9mL
Hydrogen sodium composition.
1.3 key instrument
A. carbon dioxide incubator: Heraeus company；
B. superclean bench: Suzhou cleaning equipment instrument plant；
C. inverted microscope: Leica company；
D.37 a DEG C thermostatted water educates case: Yuyao City east electric instrument factory；
E. 96 hole of Polystyrene plastic plate (ELISA Plate), tissue culture plate (96 holes and 24 holes): NEST company；
F. centrifuge: Eppendorf company
G. pure water meter: Milipore company
H. miniature vertical disk electrophoresis slot: Bio-Rad company
I. microplate reader: TECAN company
2, method
2.1 cell culture: myeloma cell SP2/0 is incubated in complete 1640 culture medium, is placed in the dioxy of 37 DEG C, 5%
Change carbon cell incubator, changes liquid 1 time, pass on 1 time every other day within 3-4 days.
The preparation of 2.2 antigens: taking 1mg human blood coagulation factor VII to be dissolved in 0.25mL DMSO solution, measures 2mmol EDC and adds
Enter in above-mentioned solution, be protected from light be aggressively shaken 2h at room temperature, 4 DEG C of reactions later are overnight.The coupling of human blood coagulation factor VII: will be above-mentioned
Solution is slowly added dropwise that (2mg albumen is dissolved in 1mL 0.1mol L in BSA solution-1In sodium bicarbonate solution), magnetic rotor is added, sets
2h is vibrated in being protected from light on magnetic force oscillator at room temperature；Reaction product is in 0.05mol L-1Dialysis is protected from light in PBS buffer solution at 4 DEG C
72h, every 5h replacement dialyzate is primary, obtains the conjugate of human blood coagulation factor VII Yu carrier protein BSA.
2.3.1 mouse immune
Balb/c mouse (4-8 week old, female) 3 is immunized in antigen after coupling, the specific steps are as follows:
A. immune for the first time: human blood coagulation factor VII-BSA100 μ g/, after adding isometric Freund's complete adjuvant to mix well
With 1mL subcutaneous multi-point injection Balb/c mouse, 0.2mL/ point；Interval 2 weeks.
B. be immunized for second: dosage and approach are same as above, and this time add isometric freund 's incomplete adjuvant, are spaced 2 weeks.
C. third time is immune: dosage is same as above, and is this time added isometric freund 's incomplete adjuvant, is taken after 10 days and mouse is immunized
Tail vein (sets 4 DEG C of refrigerator overnights after acquisition, next day stays supernatant spare after ten minutes with 2000 revs/min of centrifugations), passes through
ELISA measures serum titer.
D. the 4th time it is immune: dosage is same as above, and adjuvant is not added, and directly intraperitoneal injection is immunized.
2.3.2ELISA method detection is by immune serum potency process:
A. detection the previous day dilutes antigen human blood coagulation factor VII to 15 μ g/mL with coating buffer, enzyme linked immunological is added
In adsorption plate, every 100 μ L of hole sets 4 DEG C of refrigerator overnights；
B. next day pours out the liquid in coated enzyme linked plate holes, with washing buffer washing totally 3 times, pats dry every time；
C. it is separately added into that (serum: PBS is respectively 1:100 with the serum to be checked of PBS row gradient dilution；1:1000；1:
2000；1:4000；1:8000；37 are set using the serum of non-immune Balb/c mouse as negative control in 1:16000) 100 hole μ l/
DEG C constant water bath box 1 hour；
D. the liquid in enzyme linked plate holes is poured out, with washing buffer washing totally 3 times, is patted dry every time；
E. sheep anti-mouse igg antibody (with the dilution of antibody diluent row 1:5000) 100 μ l of HRP label are added in every hole, set
37 DEG C constant water bath box 1 hour；
F. the liquid in enzyme linked plate holes is poured out, with washing buffer washing totally 3 times, is patted dry every time；
G. develop the color: being added the tmb substrate solution 50 μ l of Extemporaneous in each reacting hole, 37 DEG C 15 minutes.
H. result judgement: microplate reader detection.
Determine that three immune mouse generate the antibody for human blood coagulation factor VII by ELISA testing result, takes wherein
The mouse of OD value highest (potency is greater than 10000) carries out subsequent step.
2.3.3 the preparation (fusion the previous day takes Turnover of Mouse Peritoneal Macrophages) of feeder cells:
Using the Balb/c female mice of 7 week old；It draws neck to put to death, is soaked in 75% alcohol and sterilizes 5 minutes, cut with sterile
Knife abdominal cut skin is to expose peritonaeum, and with the incomplete 1640 culture medium of asepsis injector per injection 8ml, repeated flushing is inhaled
Flushing liquor is put into 50mL centrifuge tube and (shares about 40mL) out, is centrifuged 5 minutes with 1300 revs/min；It abandons after supernatant with complete 1640
Precipitating is resuspended in culture solution, and adjustment cell number is 4 × 105A/mL, be added 24 porocyte culture plates, 500 holes μ l/, be put into 37 DEG C,
5% carbon dioxide cell incubator culture.
2.3.4 cell fusion
A. observe myeloma cell SP2/0 state (it is required that best in logarithmic growth phase), by prepared 50%PEG and
The incomplete 1640 culture medium of 20mL is put into 37 DEG C of cell incubator preheatings；It (preparation of 50%PEG: is prepared in fusion the previous day
It is spare that 50% PEG sets 4 DEG C of refrigerators, the PEG of 1g be put into penicillin bottle postposition pressure cooker after high pressure sterilization about liquid
1mL, the PEG that 1mL is added in the inner prepare liquid up to 50% PEG)；
B. SP2/0 is collected in 50mL sterile centrifugation tube and counted (it is required that total number of cells are 1 × 106It is a), centrifugation 1300
Rev/min, totally 7 minutes；
C. sterilized petri dishes, sieve, penicillin bottle are got out, draws neck to put to death by four immune BLAB/c mouse, sets
It is impregnated 5 minutes in 75% alcohol；
D. SP2/0 murine myeloma cell is taken to mix with immune Balb/c Mouse spleen cells in the ratio of 1:5-1:10
Uniformly, 1300rpm is centrifuged 7 minutes, abandons supernatant, is tapped tube bottom with palm, is kept cell loosely uniform；
E. the preheating of 40 DEG C of metal baths is set, is added in 45s with 1mL suction pipe and is preheated to 40 DEG C of 1mL50%PEG4000, side
Edged gently vibrates；
F. 1640 incomplete culture mediums that 30mL is preheated to 37 DEG C are then added in 90s, are stored at room temperature 10 minutes；
G.1000rpm it is centrifuged 5 minutes, abandons supernatant, 1640 culture base weights of the 20mL containing 20% fetal calf serum and HAT are added
It is outstanding, it is dispensed on the culture plate of existing feeder cells, in 5% carbon dioxide incubator culture.
2.3.5 the selectivity culture of hybridoma
Fusion was initially added into selection culture solution after 24 hours, and detailed process is as follows:
A. it after merging 24 hours, is added in the complete 1640 culture medium of 20mL and is mixed with HAT 1.6mL and HT 0.4mL, be added
In 24 orifice plates, 500 holes μ l/；
B. liquid is changed after 5 days, after 1500 μ l are sucked out in hole every in 24 orifice plates, it is (every that the quasi- complete 1640 culture medium changed is added
The HT composition of the HAT and 0.6mL of 0.6mL is added in the complete 1640 culture medium of 60mL)；
C. liquid is changed after 7 days again, after 1500 μ l are sucked out in hole every in 24 orifice plates, the quasi- complete 1640 culture medium changed is added
(the HT composition of 1.2mL is added in the complete 1640 culture medium of every 60mL.).
After carrying out step c 3 to 7 days, the cell grown in the culture hole of cell colony in 24 orifice plates is collected, is carried out subsequent
Step.
2.3.6 the identification of the hybridoma of anti-human coagulation factor VII polyclonal antibody is secreted
The Hybridoma Cell Culture that will be obtained in 2.3.5 takes its culture supernatant to carry out following step:
A. be coated with: it is 2 μ g/mL that antibody, which is diluted to protein content, with the carbonate of 0.05M pH9.6 coating buffer.
Add 50 μ l in the reacting hole of each polystyrene board, 4 DEG C overnight.Next day discards solution in hole, is washed 3 times with washing buffer,
3 minutes every time (referred to as washing, similarly hereinafter).
B. it closes: adding the 300 μ l of skimmed milk power (BD company) PBS containing 5% in the reacting hole of each polystyrene board,
It sets 37 DEG C to be incubated for 2 hours, be washed out.
C. it is loaded: adding certain diluted 50 μ l of measuring samples in the above-mentioned reacting hole being coated with, it is small to set 37 DEG C of incubations 1
When, it is washed out (while doing blank well, negative control hole and Positive control wells).
D. enzyme labeling antibody: in each reacting hole, the enzyme labelled antibody of diluted is added, and (by specification carries out dilute
Release) 50 μ l.37 DEG C are incubated for 1 hour, washing.
Plus substrate solution colour developing e.: be added the tmb substrate solution 50 μ l of Extemporaneous in each reacting hole, 37 DEG C 15 minutes.
F. it terminates reaction: 50 μ l of 2M sulfuric acid being added in each reacting hole.
G. result judgement: can be in the result that in white background, directly detects by an unaided eye: color be deeper in reacting hole, positive journey
Degree is stronger, and to be colourless or extremely shallow, the depth of the be in color of foundation is indicated negative reaction with "+", "-" number.It can also be examined in ELISA
It surveys on instrument in 450nm and 630 double UV check OD values, each hole OD value is surveyed after returning to zero with blank control wells, if more than defined yin
Property control 2.1 times of OD value, it is as positive.
H. result: detecting culture supernatant by microplate reader, for the positive.
2.3.7 it the expansion culture of hybridoma and freezes
A. expand culture: taking the polyclonal cells of the supernatant positive to be transferred to culture in 24 orifice plates (1 hole turns 1 hole), in 24 after 3 days
It is divided into 4 holes after being divided into 2 holes, then 3 days in orifice plate, then after 2 days the cell in this 4 hole is transferred to 50mL Tissue Culture Flask together and expanded
Culture.Wherein a strain of hybridoma is named as F7-P-01.
B. hybridoma freezes: when 50mL culture bottle inner cell is paved with bottom of bottle area about 70% → will be in culture bottle
Cell cut and beat with suction pipe, so that it is suspended completely, cell suspension moved into the centrifugation 1200 in 50mL sterile centrifugation tube and counting
Rev/min, 6 minutes → abandon supernatant, with cells frozen storing liquid (cells frozen storing liquid composition: 50% fetal calf serum；40% incomplete 1640 training
Nutrient solution；Precipitating 10%DMSO) is resuspended, adjusting cell density is 1 × 107/ L → is sub-packed in cryopreservation tube, 1mL/ branch → set -70 DEG C of ice
Case overnight → cell frozen is concealed in liquid nitrogen by next day.
2.3.8 the mass production of polyclonal antibody
By taking hybridoma cell strain F7-P-01 as an example, the Balb/c female mice of 10 8-10 week old is taken first to use atoleine
Pre-sensitization is only injected intraperitoneally in 0.3mL/, and hybridoma cell strain F7-P-01 is collected after 1 week with 1 × 106A/(same amount of normal saline
Be diluted to 1mL/ only) amount the mouse of above-mentioned pre-sensitization is injected intraperitoneally, observed after 10-14 days mouse abdominal distension obviously, be slow in action,
Ascites is collected when do not feel like eating and hair entanglement, neck is drawn to put to death mouse, is sucked ascites in centrifuge tube with clean dropper, centrifugation
2000 revs/min, 5 minutes.
As a result: being the positive through ELISA method detection ascites.
The identification of 2.4 polyclonal antibody subclass
Using mouse polyclonal antibody subclass parting kit (Thermo company), specific steps are referring to its specification.
As a result: through kit measurement, the polyclonal antibody hypotype of gained hybridoma cell strain F7-P-01 secretion is IgM.
2.5 immunoblottings (Western blotting)
2.5.1 sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
A. conventionally preparative separation glue and spacer gel；
B. take a certain amount of protein example and isometric 2 × SDS sample-loading buffer (100mmol/l Trisbase,
200mmol/l dithiothreitol (DTT), 4%SDS, 0.2 bromine Finland, 20%Glycerol) mixing, it is denaturalized 5 minutes in 100 DEG C；
C. it is loaded in discontinuous polyethylene acrylamide gel sample well according to every swimming lane 100ug；
D. gel bottom edge is arrived at constant pressure 50V (spacer gel)/100V (separation gel) electrophoresis to bromophenol blue；
E. it takes out gel and is used for Western blotting.
2.5.2Western blotting
The transferred buffer of a.SDS-PAGE gel (25mmol/l Tris base, 192mmpl/l Dlycin, 20% first
Aldehyde) it impregnates 10-20 minutes；
B. tower is shifted according to the sequence assembled box type of 3 filter paper, gel, NC film, 3 filter paper, and it is faced south with NC film
The direction of pole is packed into transfer device；
C. under room temperature, current stabilization 0.8mA/cm2Electrotransfer, the time 90 minutes；
D. NC film is dyed with Ponceaux dye liquor, with marker pen labelled protein molecular weight standard amount, each band institute is in place
It sets, then Ponceaux is washed with deionized water；
E.NC film is closed 2 hours through 10% skimmed milk power in room temperature；
F. be diluted in 5% skimmed milk power antibody (freshly prepd polyclonal antibody 1:1000, anti-β-actin 1:5000) 4
DEG C be incubated overnight, TBST (10mmol/l Tris base, 150mmol/l NaCl, 0.05%Tween20, pH8.0), which shakes, to be washed 4 times
× 15 minutes；
G. the sheep anti-mouse igg marked with the HRP for being diluted in 4% skimmed milk power was in incubation at room temperature 4 hours；
H.TBST, which shakes, washes totally 4 times, 15 minutes/time；
I. A+B liquid in mixed in equal amounts ECL Color Appearance System, is added dropwise to NC film；
J. it is imaged.
K. result: being detected with the ascites that hybridoma F7-P-01 is generated through mouse peritoneal injection through WesternBlot method proves
The polyclonal antibody that the hybridoma cell strain generates can identify human blood coagulation factor VII.
Claims (1)
1. a kind of hybridoma cell strain for secreting anti-human coagulation factor VII polyclonal antibody, it is characterised in that: the hybridoma is thin
Born of the same parents' strain is to be named as F7-P-01, is preserved in China typical culture collection center on November 6th, 2015, deposit number is
The hybridoma cell strain of CCTCC C2015195, wherein the polyclonal antibody hypotype of hybridoma cell strain F7-P-01 secretion
For IgM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510792378.4A CN105349524B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VII polyclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510792378.4A CN105349524B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VII polyclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105349524A CN105349524A (en) | 2016-02-24 |
| CN105349524B true CN105349524B (en) | 2019-02-22 |
Family
ID=55325586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510792378.4A Active CN105349524B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VII polyclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105349524B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101906159A (en) * | 2010-06-21 | 2010-12-08 | 南京农业大学 | Hybridoma cell line D6D |
-
2015
- 2015-11-17 CN CN201510792378.4A patent/CN105349524B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101906159A (en) * | 2010-06-21 | 2010-12-08 | 南京农业大学 | Hybridoma cell line D6D |
Non-Patent Citations (3)
| Title |
|---|
| 人凝血因子VII单克隆抗体的制备与应用初探;徐世洲;《中国优秀硕士学位论文全文数据库（硕士） 基础科学辑》;20061115(第11期);第10页倒数第1段-第32页第1段 * |
| 人凝血因子VII单克隆抗体的制备与鉴定;吕茂民等;《生物技术通讯》;20081231;第19卷(第1期);第73-75页 * |
| 人肝脏凝血因子XI的原核表达及其兔多克隆抗体的制备;吕鑫钰等;《哈尔滨医科大学学报》;20140831;第48卷(第4期);第274-281页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105349524A (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heinz et al. | A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies | |
| CN106589124B (en) | CD146 monoclonal antibody detects and separates the application in identification in glioma perivascular cell | |
| CN105273083A (en) | Anti-human aryl hydrocarbon receptor monoclonal antibody and application thereof | |
| CN105349496B (en) | The hybridoma cell strain of anti-macroglobulin monoclonal antibody | |
| CN101793897A (en) | Method for improving screening efficiency of hybridoma | |
| CN105349495B (en) | The hybridoma cell strain of anticoagulin IX monoclonal antibody | |
| CN105400769B (en) | The hybridoma cell strain of anticoagulin VIII monoclonal antibody | |
| CN101985476B (en) | Preparation, identification and application of antihuman NKp30 monoclonal antibody | |
| CN105349524B (en) | The hybridoma cell strain of anticoagulin VII polyclonal antibody | |
| CN105349497B (en) | Hybridoma cell strain of anti-alpha-antitrypsin polyclonal antibody | |
| CN101717447A (en) | Method for preparing antihuman recombinant tissue factor monoclonal antibody | |
| CN106381289A (en) | Monoclonal antibody of resisting 25-hydroxyvitamin D3 as well as preparation cell lines and method of monoclonal antibody | |
| CN104789535B (en) | Anti- methadone metabolin EDDP hybridoma cell strains and its preparation method and application | |
| CN101240021B (en) | Monoclonal antibody for anti-human CDK5RAP2 protein and application thereof | |
| CN107058240A (en) | One strain of hybridoma strain AB1 and its 2,4,5 trichlorophenoxyacetic acid monoclonal antibodies of generation | |
| CN104693305A (en) | Anti-human glycosphingolipid Globo-H monoclonal antibody and preparation method and application thereof | |
| Kudo et al. | Production of a human monoclonal antibody to a synthetic peptide by active in vivo immunization using a SCID mouse grafted with human lymphocytes | |
| CN111961002A (en) | Pyraclostrobin hapten, artificial antigen and antibody as well as preparation method and application thereof | |
| CN109336974A (en) | A kind of preparation method of anti-TMP rabbit polyclonal antibody | |
| KLOCK et al. | Human hybridoma generation by hypo-osmolar electrofusion: characterization of human monoclonal antibodies to Schistosoma mansoni parasite antigens | |
| CN115232798B (en) | Hybridoma cell strain 5B3, orientia tsutsugamushi 56kDa protein monoclonal antibody, and preparation method and application thereof | |
| CN114591437B (en) | RAC1 protein monoclonal antibody and preparation method and application thereof | |
| RU2265658C2 (en) | Strain of hybrid cells of animal mus musculus l, 9e2, used in preparing monoclonal antibody to west nile virus protein e of strain wnv/leiv-vig99-27889 | |
| RU2117042C1 (en) | Strain of cultured hybrid cells of animal mus musculus - producer of monoclonal antibodies to thermostable component of capsule-like substance of meliodosis pathogen | |
| CN107064504A (en) | A kind of method of lysozyme in detection egg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |